Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Two champions ... continued their sponsorship of an annual competition for middle ... and access to, innovative STEM study. The competition presents ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 2013 was ... Scottsdale’s Brain State Technologies®. They saw continued independent research ... Center who were awarded a $1 million grant from ... in “Brain and Behavior” a peer reviewed journal, Amy ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Real-Time Location System provider for healthcare, is pleased to ... Real-Time Location System . The new messaging better captures ... – , Industry-Leading Accuracy , ... Applications Easy Installation and Maintenance ...
... been mysteriously falling for at least five years in the ... (CCD) is still largely unknown. In a report ... , researchers report that a widely used in-hive medication may ... and that this interaction may be at least partially responsible ...
... and SHENZHEN, China, Nov. 2, 2011 Advanced BioMedical ... internal fixation devices, is pleased to announce the formation ... comprised of three distinguished physicians and scientists. The combined ... critical scientific and strategic input as the Company continues ...
Cached Biology Technology:CenTrak, a Leading Real-Time Location System Provider, Unveils New Branding 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 2Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 3Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 4Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 5Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 6Advanced BioMedical Technologies Inc. Announces Formation of Scientific Advisory Board 7
(Date:4/24/2014)... recently introduced Clinical OMICs ... of OMICs technologies in clinical settings. These advanced ... transform medical care just as they revolutionized basic ... "GEN,s editors and reporters have written about the ... etc. for years," said John Sterling, editor-in-chief of ...
(Date:4/24/2014)... cheap way of making a high-powered lens that can ... Costing less than a cent, the lenses promise a ... remote areas. , The lens fabrication technique was invented ... (ANU) Research School of Engineering, who collaborated with Dr ... to find ways to transform the lentil-sized lens into ...
(Date:4/24/2014)... University of North Carolina at Chapel Hill have developed ... plaque that is at high risk of breaking off ... is the plaque that builds up in arteries as ... meaning that they are more likely to detach from ... , "Existing state-of-the-art technologies are capable of determining if ...
Breaking Biology News(10 mins):Droplet lens 2New ultrasound device may add in detecting risk for heart attack, stroke 2
... 2009 Landfilled waste decomposes in the absence ... methane. Landfills are classified as the second-largest human-made ... gas contains numerous non-methane hydrocarbons that are either ... biochemical reactions during waste degradation. Microbial methane ...
... tissues need continuous irrigation and drainage. Blood vessels feeding ... via the lymphatic system. While much is known about ... true for lymph vessels. Now though, Norrmn et al. ... drainage construction in the mouse embryo. The ...
... the composition and structure of a needlelike protein complex ... develop new strategies to thwart infection. The research, conducted ... National Laboratory, will be published April 26, 2009, in ... Molecular Biology . The scientists were studying a ...
Cached Biology News:Landfill cover soil methane oxidation underestimated 2Details of bacterial 'injection' system revealed 2
... antibiotic-based selection system for recombinant identification. Recombinant ... the need for costly color screening. This ... 100% accuracy in recombinant selection. pLivSelect is ... picking. This cloning kit can be used ...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
...
Biology Products: